Clinical Implications (ALI/ARDS): Given the narrow therapeutic window in ALI/ARDS, early intervention integrating anti-ferroptosis and anti-NET approaches with METTL3 inhibition may offer maximal protection of epithelial–endothelial barrier integrity. The gene discussed is METTL3; the disease is acute respiratory distress syndrome.